Brief: Arcutis And Padagis Agree To Stay Patent Lawsuit
02/04/2025 20:29
April 2 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O: ARCUTIS AND PADAGIS AGREE TO STAY PATENT LAWSUIT ARCUTIS BIOTHERAPEUTICS: PADAGIS TO REPORT TO CO ANY FDA CORRESPONDENCE ABOUT ANDA FOR THEIR GENERIC ALTERNATIVE TO ZORYVE CREAM 0.3% Source text: ID:nGNX8Jts1x Further company coverage: ARQT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Canada Przoryve Cream 0.05% Receives Health Canada Approval For Atopic Dermatitis
Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
Arcutis Biotherapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview
Brief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4